Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.

The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g. blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g. blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Provided herein are conjugated oligonucleotides including a linker with one or more hydrophobicity- or valency-modulating headgroups Z.sup.c having the structure of formula (II):

##STR00001## wherein: Y is selected from the group consisting of [NR.sub.3].sup.+, [SR.sub.2].sup.+, NR.sub.2, and CH(NH.sub.2)CO.sub.2H, wherein each R is independently selected from the group consisting of hydrogen, and optionally substituted C1-C9 alkyl, C1-C9 heteroalkyl, C1-C9 alkenyl, C1-C9 heteroalkenyl, C1-C1 alkynyl, and C1-C9 heteroalkynyl groups; B is a bridge group selected from the group consisting of substituted or unsubstituted C2-C9 alkyl, C2-C9 heteroalkyl, C2-C9 alkenyl, C2-C9 heteroalkenyl, C2-C9 alkynyl, and C2-C9 heteroalkynyl groups; X.sup.1 is absent, an oxygen atom, or NH; X is oxygen, sulfur or borane; useful for RNA interference (RNAi).